Drug shortage
Hydrocortisone Sodium Succinate Injection · Hospira, Inc., a Pfizer Company
FDA drug shortage · Current · updated Apr 11, 2025
Key facts
| Generic name | Hydrocortisone Sodium Succinate Injection |
|---|---|
| Proprietary name | Solu-Cortef |
| Company | Hospira, Inc., a Pfizer Company |
| Presentation | Solu-cortef, Injection, 1000 mg/vial (NDC 0009-0005-01) |
| Dosage form | Injection |
| Strength | 1000 mg/vial |
| Status | Current |
| Therapeutic category | Dermatology Endocrinology/Metabolism Gastroenterology Hematology Neurology Oncology Ophthalmology Pediatric Pulmonary/Allergy Renal Rheumatology |
| Package NDCs | 0009-0005-01 |
| First posted | Mar 24, 2023 |
| Last updated | Apr 11, 2025 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: